Invivyd (IVVD) said Tuesday that it plans to launch a mid-stage clinical trial, along with the SPEAR Study Group, that assesses the safety, translational biology, and exploratory clinical efficacy of investigational antibody VYD2311 in individuals with Long COVID or COVID vaccine injury.
The trial will evaluate multiple high doses of the antibody across many months of therapy, the company said.
The mid-stage trial is expected to begin by mid-2026, with further details to be announced in the coming months, Invivyd said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments